SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm|Breast Cancer|Hormone Receptor Positive Tumor|HER2-negative Breast Cancer|Advanced Breast Cancer
Interventions: DRUG: PIK3CA inhibitor|DRUG: AKT inhibitor|DRUG: Carrelizumab|DRUG: Famitinib|DRUG: Fluzoparib|DRUG: Dalpiciclib|DRUG: SHR-A1811|DRUG: TROP2 ADC|DRUG: Everolimus|DRUG: Aromatase Inhibitors or Fulvestrant|DRUG: Goserelin|DRUG: TPC|DRUG: RTK Inhibitor
Sponsor: Fudan University
Collaborators: Peking University Cancer Hospital & Institute|First Hospital of China Medical University|Sun Yat-sen University|First Affiliated Hospital Xi'an Jiaotong University|Chongqing University Cancer Hospital|Northern Jiangsu People's Hospital|Fujian Medical University Union Hospital|Ningbo Medical Center Lihuili Hospital|Shanghai First Maternity and Infant Hospital|Shanghai 6th People's Hospital|Affiliated Hospital of Nantong University